US-based cardiovascular biopharmaceutical company Cytokinetics Inc (Nasdaq:CYTK) and German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) announced on Tuesday a collaboration and licence agreement for the development and commercialisation of aficamten in Japan.
Aficamten is a next-generation cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy (HCM).
Under the terms of the agreement Cytokinetics will receive upfront payments and milestone payments, as well as tiered royalties on future sales of aficamten in Japan.
Bayer will conduct a Phase 3 clinical trial in Japanese patients with obstructive HCM, while Cytokinetics will expand its ongoing ACACIA-HCM and CEDAR-HCM trials to include Japanese patients.
This partnership aims to bring aficamten to patients with HCM in Japan and address a significant unmet medical need.
Neurizon Therapeutics reports breakthrough preclinical results for ALS treatment candidate NUZ-001
Cytokinetics and Bayer partner on aficamten for Japanese HCM patients
Nektar Therapeutics announces 2024 ACR conference oral presentation of NKTR-422 preclinical data
GRAIL reports first patient tested with blood-based assay in TROPION-Lung12 Phase 3 study
SK Biopharmaceuticals enters radiopharmaceutical therapy research agreement
Adicet Bio doses first patient in Phase 1 trial of ADI-001 for lupus nephritis
Cybin's CYB003 shows 12-month efficacy in Phase 2 MDD trial
Scancell reports promising SCOPE trial data for SCIB1 in advanced melanoma
AstraZeneca's Tagrisso Recommended for EU approval for unresectable EGFR-mutated lung cancer
Martin Pharmaceuticals announces DREAM study results at 75th Annual Liver Meeting of AASLD
Rona Therapeutics reveals positive outcome from RN0191 phase one clinical trial
Merck's KEYTRUDA plus chemotherapy receives positive EU opinion for first-line MPM treatment
Sanofi seeks FDA approval for Dupixent in chronic spontaneous urticaria